Kornimate/medical-research-clean huggingface dataset:
tissue glue (cyanoacrylate) versus conventional suture in kidney donors

Conditions: Skin Closure of Surgical Incisions by Tissue Glue vs Suture

Summary: by means of a prospective, randomised trial the investigators want to examine skin closure in living donors - subjected to laparoscopic, hand-assisted nephrectomy - by tissue glue (cyanoacrylate (liquiband)) versus conventional, intracutaneous suture and dressing (1 : 1; 30 + 30 donors). study hypothesis: (i) latest generation tissue glue (cyanoacrylate (liquiband)) is at least as good as conventional suture regarding wound healing/complications. (ii) peroperatively, tissue glue is faster than conventional suture.

at oslo university hospital rikshospitalet, the principal investigator have since 1998 been involved in developing minimally invasive techniques for living donor nephrectomy (ldn). since 2009 all ldn's have been performed by laparoscopic, hand-assisted technique; by means of 'handport' and 3 laparoscopic ports (5/12 mm). the investigators consider use of tissue glue instead of suture as another small step towards less invasive surgery. since 2000 there has been many reports, and even cochrane reviews on the use/safety of tissue glue for skin closure. however, very few randomised studies have been performed with the latest generation tissue glue; cyanoacrylate, with a critical mixture of octyl-:butyl-acrylate. and in norway there has been no research in this field. on this basis, the investigators intend to examine skin closure in living donors, a very healthy/homogenous study population, subjected to laparoscopic, hand-assisted nephrectomy, by a prospective, randomised trial: tissue glue (cyanoacrylate (liquiband)) versus conventional, intracutaneous suture and dressing (1 : 1; 30 + 30 donors). primarily, the investigators will examine wound healing/complications by wound observation at postop. days 2 + 4 + 'at departure', with numerical scales for secretion, gaps, edema, rubor - as well as infection/bacteriology and complications/ reinterventions. in addition, the donors' self-satisfaction with the wound handling will be registered. furthermore, the investigators will look at time consumption during surgery, price, stay in hospital and cosmesis judged at 2-3 months postoperatively.

Eligibility criteria:
inclusion criteria: * living kidney donor with informed consent * approved comprehensive work-up/evaluation at local hospital exclusion criteria: * allergy towards acrylate or similar chemicals * unable to communicate in norwegian language

Keywords: tissue glue cyanoacrylate wound closure living donor nephrectomy surgical wound closure
genetic mutational analysis of saliva or buccal mucosa samples from patients with embryonal or alveolar rhabdomyosarcoma

Conditions: Alveolar Rhabdomyosarcoma; Embryonal Rhabdomyosarcoma

Summary: this research trial studies genetic mutations in saliva or buccal mucosa samples from patients with embryonal or alveolar rhabdomyosarcoma. identifying gene mutations may help doctors learn about the prognosis of patients with embryonal or alveolar rhabdomyosarcoma.

primary objectives: i. to identify novel recurrent de novo germline mutations among rhabdomyosarcoma (rms) case-parent trios. ii. to identify the frequency of de novo germline mutations in cancer predisposition genes among rms case-parent trios. secondary objectives: i. to conduct ?deep phenotyping? of children diagnosed with rms utilizing questionnaire data and information from medical records. outline: patients and their parents undergo collection of saliva or buccal mucosa samples for genetic mutational analysis. germline deoxyribonucleic acid (dna) from saliva or buccal mucosa is evaluated via whole exome sequencing.

Eligibility criteria:
inclusion criteria: * the patient must be enrolled on accrn07 and/or apec14b1 and registered with cog by a north american member institution * the patient must have a diagnosis of embryonal rhabdomyosarcoma or alveolar rhabdomyosarcoma * the patient must be diagnosed with rhabdomyosarcoma between january 1, 2012 and november 30, 2019 * concomitant treatment on a therapeutic trial is not required * the patient must have at least one biological parent alive and willing to participate * all questionnaire respondents must understand english or spanish * all patients and/or their parents or legal guardians must sign a written informed consent * all institutional, food and drug administration (fda), and national cancer institute (nci) requirements for human studies must be met
a prospective multicentre real-world assessment of the efficacy of danning tablets in alleviating digestive symptoms

Conditions: Indigestion; Dyspepsia; Bloating; Loss of Appetite; Reflux Acid; Constipation; Upper Abdominal Pain; Functional Dyspepsia

Summary: the goal of this observational study is to evaluate if danning tablets are effective in alleviating dyspepsia in patients with any of the following digestive symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation. the main questions it aims to answer are: how effective are danning tablets for patients with indigestion symptoms? what are the impact factors (e.g. severity of conditions, demographic features, dose and length of treatment etc.) of the efficacy of danning tablets for indigestion patients? participants already taking danning tablets as part of their regular medical care for indigestion will take questionnaires by the end of two weeks and four weeks respectively from the start of their treatment.


Eligibility criteria:
inclusion criteria: * patients between 18 and 75 years old * patients with at least one of the following symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation * patients already taking danning tablets as part of their regular medicine treatment for dyspepsia * patients agree to sign the informed consent form exclusion criteria: * past history or comorbidity of malignant tumor * comorbidity of severe systemic condition including cardiovascular, cerebrovascular, renal and hematopoietic system diseases * past history of abdominal surgery (post pancreatic surgery, post subtotal gastrectomy; incomplete intestinal obstruction) or mental illness, mobility difficulty (e.g. long-term bed ridden) * comorbidity of any unstable chronic or acute disease,which may impact the evaluation of treatment efficacy as determined by the research physician * pregnancy or breastfeeding * participation in other clinical trials within the past 3 months * other circumstances determined as ineligible by the research physician

Keywords: danning tablets dyspepsia indigestion observational study real world study
"sport on prescription" in primary care for patients with long-term illnesses

Conditions: Chronic Illness

Summary: adapted physical activity (apa) helps to prevent chronic diseases identified as major causes of mortality, particularly cardiovascular diseases and some cancers, according to the world health organization (who). however, in general population, physical activity levels are below recommendations for nearly 40% of french adults. in france, general practitioners are now authorised and encouraged to prescribe apa to long-term illness patients. in var department in france, the " maison sport-santé 83 " has set up a program called "cap sport santé 83" to support patients who received a prescription to practice apa on a regular basis. this program helps long-term illness patients to restart physical activity by considering their pathology. the aim of this study is to evaluate " maison sport-santé 83 " apa program effectiveness using a rigorous scientific methodology.


Eligibility criteria:
inclusion criteria: * patient with a long-term illness of any type, or a chronic illness, or risk factors (such as hypertension or obesity), or persons with decreasing independance and a stabilised clinical condition * aged 18 years old or over * able to express his/her consent prior to participation in the study * understanding french language * affiliated to or beneficiary of a social security regimen exclusion criteria: * patient with a contraindication to physical activity * pregnant women * patient under judicial protection (guardianship, curatorship...) or safeguard of justice * any other reason that, in the opinion of the investigator, might interfere with the evaluation of the study objectives

Keywords: chronic disease adapted physical activity prescription quality of life
observational study of corneal opacities in adults

Conditions: Corneal Opacities (Scar and Stromal Dystrophy)

Summary: a prospective observational study on corneal opacities (scar and stromal dystrophy) in adults (n=150) will be conducted at ohsu. the optovue anterior segment oct will be used to perform 3-d corneal scans. these scans will be used to assess opacity depth and measure corneal thickness (pachymetry), corneal topography (anterior and posterior), and epithelial thickness maps. the ultrahigh-speed mit oct prototypes will also be used when they become available. a comprehensive eye examination, placido-ring corneal topography, ultrasound pachymetry, and scheimpflug camera imaging, will be performed for comparison.


Eligibility criteria:
inclusion criteria: • adult (18 \& older) patients presenting in ohsu casey eye clinic with corneal opacities (scar and stromal dystrophy) exclusion criteria: * inability to give informed consent. * inability to maintain stable fixation for oct imaging. * inability to commit to required visits to complete the study.

Keywords: corneal opacities optical coherence tomography
retrospective palivizumab study in children with hemodynamically significant congenital heart disease

Conditions: Severe Respiratory Syncytial Virus Infection

Summary: retrospective medical record review study of specific adverse events in children with congenital heart disease who received palivizumab for prophylaxis of serious respiratory syncytial virus infection and control subjects that did not receive palivizumab

this is an observational, non-interventional, retrospective cohort study of infants with hemodynamically significant congenital heart disease (hschd) who were less than 24 months of age when the first dose of palivizumab was administered (cases), and infants who were diagnosed with hemodynamically significant congenital heart disease but did not receive palivizumab in a historical respiratory syncytial virus (rsv) season during the first 24 months of life (controls). cases are matched to controls based on rsv season, age, type of cardiac lesion, and type of prior corrective cardiac surgery. subject medical records are reviewed for occurrences of the clinical end points of infection, arrhythmia, and/or death that meet criteria for serious adverse events. the groups will be compared for number and percent of subjects who experience these primary serious adverse events (both individually and collectively) during a defined 8-month chart review period.

Eligibility criteria:
inclusion criteria: 1. subject must have documented hemodynamically significant congenital heart disease (note: children with uncomplicated small atrial or ventricular septal defects or patent ductus arteriosus are not eligible). 2. subject must have unoperated or partially corrected congenital heart disease. 3. subject must have received at least one dose of palivizumab for prophylaxis during the respiratory syncytial virus season - september 1 through april 30 (cases), or would have been considered eligible for palivizumab prophylaxis (controls). 4. subject must be \< 24 months of age at the time of the first dose of palivizumab prophylaxis (cases) or \< 32 months of age at the end of the assigned respiratory syncytial virus season in which they would have been eligible to receive palivizumab if the drug had been approved in the european union (controls). 5. subject's parent, guardian, or legal representative has voluntarily signed and dated a release of information form to allow the review of medical records and collection of pertinent study data. exclusion criteria: 1. subject was contraindicated for treatment with palivizumab according to the current european product label. 2. subject had full correction of congenital heart disease. 3. subject received palivizumab before approval for use in congenital heart disease (cases), or subject received palivizumab at any time (controls). 4. subject has already been included in this study in a prior respiratory syncytial virus season.

Keywords: infection arrhythmia death palivizumab safety hemodynamically significant congenital heart disease pediatric observational
vaccine therapy following chemotherapy & peripheral stem cell transplantation in treating non-hodgkin's lymphoma

Conditions: Lymphoma

Summary: rationale: vaccines made from a person's cancer cells may make the body build an immune response to kill cancer cells. vaccine therapy may be an effective treatment for non-hodgkin's lymphoma. purpose: phase ii trial to study the effectiveness of vaccine therapy following chemotherapy and peripheral stem cell transplantation in treating patients who have non-hodgkin's lymphoma.

objectives: * determine the humoral and cellular immune responses in patients with follicular non-hodgkin's lymphoma treated with autologous lymphoma-derived idiotype vaccine with keyhole limpet hemocyanin plus sargramostim (gm-csf). * determine the safety and toxicity of this regimen in these patients in the post-transplant setting. * determine the changes in quantitative bcl-2 in the blood and bone marrow of these patients before and at various times after the series of idiotype vaccines. outline: vaccinations begin at day 100 or up to 6 months after hematopoietic stem cell transplantation. patients receive autologous lymphoma-derived idiotype vaccine plus keyhole limpet hemocyanin subcutaneously (sc) on day 1. sargramostim (gm-csf) sc is administered on days 1-4. treatment repeats every 4 weeks for 4 doses, followed 12 weeks later by the fifth and final dose. patients are followed every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter. projected accrual: a total of 20 patients will be accrued for this study.

Eligibility criteria:
inclusion criteria: * over 19 years of age * histologically proven grade i, ii, or iii follicular non-hodgkin's lymphoma that failed induction therapy * minimal disease state at day 100 to 6 months post-transplantatio * lymph nodes smaller than 2 centimeters (cm) * less than 20% bone marrow involvement with lymphoma * uncertain complete remission, defined by greater than 75% reduction in the size of the pre-transplantation mass not representing active disease * tissue sample safely accessible by biopsy, needle aspiration, or phlebotomy o must have adequate circulating lymphoma cells * karnofsky greater than 70% * absolute neutrophil count greater than 1,000/mm\^3 (no restrictions if study vaccine administered at 6 months after transplantation) * cd4+ count greater than 200/microliter (no restrictions if study vaccine administered at 6 months after transplantation) * bilirubin less than 2.0 mg/dl (unless due to lymphomatous involvement) * serum glutamic oxaloacetic transaminase (sgot) and serum glutamic pyruvic transaminase (sgpt) less than 2 times normal (unless due to lymphomatous involvement) * creatinine no greater than 2.0 mg/dl * fertile patients must use effective contraception during and for 6 months after study participation exclusion criteria: * previously received no more than 2 high-dose chemotherapies before hematopoietic stem cell transplantation * not pregnant or nursing/negative pregnancy test

Keywords: recurrent grade 1 follicular lymphoma recurrent grade 2 follicular lymphoma recurrent grade 3 follicular lymphoma
transcranial direct current stimulation (tdcs) for treatment of negative syndrome in patients with schizophrenia

Conditions: Schizophrenia

Summary: transcranial direct current stimulation (tdcs) showed beneficial effects on cognition in healthy subjects and depressed patients. in this study, patients with treatment resistant negative syndrome in schizophrenia will be treated with direct current stimulation. fmri measures will be performed.


Eligibility criteria:
inclusion criteria: * schizophrenic patients with a negative syndrome. panss \> 40. exclusion criteria: * other psychiatric or neurologic diseases.

Keywords: schizophrenia negative syndrome panss
enb-gs-tblb for the diagnosis of ppls

Conditions: Lung Cancer

Summary: the purpose of this study is to evaluate the efficacy and safety of electromagnetic navigation bronchoscopy with a guide sheath(enb-gs) for the diagnosis of peripheral pulmonary lesions (ppls) .

the investigators evaluated the efficacy and safety of transbronchial lung biopsy (tblb) and bronchial brushing using electromagnetic navigation bronchoscopy (enb) with a guide sheath (gs) for the diagnosis of peripheral pulmonary lesions (ppls) with radiographic fluoroscopy.the study is designed as a two-center prospective randomized controlled trial. the participating centers are department of pulmonary medicine and endoscope department, shanghai chest hospital affiliated to shanghai jiaotong university, china. department of pulmonary medicine, shanghai zhongshan hospitial affiliated to shanghai fudan university, china.patients are divided into two groups, enb-gs-tblb-x-ray group and gs-tblb-x-ray group.each subject will be randomized to each group.the study is expected to enroll 60 patients at 2 centers (shanghai chest hospital: 40, shanghai zhongshan hospital: 20).

Eligibility criteria:
inclusion criteria: 1. clinical and imaging characteristics suggestive of maligancy 2. ct scan appearance of the ppls showed the longest diameter was more than 1 cm and solid lesions. exclusion criteria: 1. the lesion is close to the pleural membrane 2. refusal of participation 3. severe cardiopulmonary dysfunction and other indications that can't receive bronchoscopy

Keywords: electromagnetic navigation bronchoscopy with a guide sheath transbronchial lung biopsy peripheral lung lesions solitary pulmonary nodule
evaluation of postoperative pain in children

Conditions: Postoperative Pain

Summary: postoperative pain is a common symptom of a flare up after root canal treatments (rcts). insufficient instrumentation, extrusion of irrigation solutions and debris and existence of a periapical lesion are the factors affecting postoperative pain after root canal treatments. aim of this study is to evaluate the postoperative pain and instrumentation time of single-file reciprocating system and multiple-file ni-ti rotary system in children ages between 9-12. study was conducted on fifty first permanent mandibular molars with the diagnosis of irreversible pulpitis. patients were randomly separated into two groups and rcts were completed with either reciproc blue or protaper next file systems. instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment. postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test. there was no statistically significant difference in postoperative pain between reciproc blue and protaper next systems at all time intervals. instrumentation time was significantly shorter in the reciproc blue group in comparison with the protaper next group. in conclusion, shorter treatment time of single-file reciprocating systems may be more patient friendly and comfortable than multiple-file rotary systems in rcts among children.


Eligibility criteria:
inclusion criteria: * patients with first permanent mandibular molar teeth which had been diagnosed with symptomatic irreversible pulpitis with no periapical pathology or abscess were included in the study. exclusion criteria: * patients who were on antibiotics or analgesics preoperatively were not included in the study.

Keywords: postoperative pain root canal treatment reciprocal motion rotary motion
dexmedetomidine supplemented analgesia and long-term survival after cancer surgery

Conditions: Elderly; Surgery; Analgesia; Dexmedetomidine; Long-term Outcome

Summary: a majority of the elderly patients undergo surgery for malignant tumors. for these patients, postoperative tumor recurrence and metastasis are main factors that worsen long-term outcomes. the investigators hypothesize that dexmedetomidine supplemented analgesia in elderly patients after cancer surgery may help to maintain immune function and improve long-term outcomes, possibly by relieving stress and inflammatory response, improving analgesic efficacy and sleep quality, and reducing delirium incidence.

a majority of the elderly patients undergo surgery for malignant tumors. for these patients, postoperative tumor recurrence and metastasis are main factors that worsen the quality of life and shorten the duration of survival. perioperative immune function is a key element that influences postoperative tumor recurrence and metastasis; but it is subject to the impacts of many factors. studies showed that elevated cortisol level and inflammation provoked by surgical stress result in suppression of immune function, whereas dexmedetomidine alleviates the elevated cortisol level and inhibit excessive inflammation; high-dose opioids inhibit the immune function and increase the invasiveness of tumor cells, whereas dexmedetomidine reduces the consumption of opioids during perioperative period; postoperative sleep disturbances also impair immune function, whereas dexmedetomidine improves sleep quality in patients after surgery; occurrence of postoperative delirium is associated with increased mortality, whereas dexmedetomidine reduces delirium incidence. the investigators hypothesize that dexmedetomidine supplemented analgesia in elderly patients after cancer surgery may improve the long-term outcomes, possibly by relieving stress and inflammatory response, improving analgesic efficacy and sleep quality, and reducing delirium incidence.

Eligibility criteria:
inclusion criteria: * age \>= 65 years, \< 90 years; * scheduled to undergo surgery for primary solid organ cancer under general anesthesia, with an expected duration of surgery \>=2 hours; * planned to use patient-controlled intravenous analgesia after surgery; * provide written informed consent. exclusion criteria: * preoperative history of schizophrenia, epilepsy, parkinsonism or myasthenia gravis; * preoperative radio- or chemotherapy; * inability to communicate in the preoperative period because of coma, profound dementia or language barrier; * preoperative obstructive sleep apnea (previously diagnosed as obstructive sleep apnea, or a stop-bang score \>= 3); * brain trauma or neurosurgery; * preoperative left ventricular ejection fraction \< 30%, sick sinus syndrome, severe sinus bradycardia (\< 50 beats per minute), or second-degree or above atrioventricular block without pacemaker; * severe hepatic dysfunction (child-pugh class c) or severe renal dysfunction (requirement of renal replacement therapy before surgery); * asa classification \>= iv.

Keywords: elderly surgery analgesia dexmedetomidine long-term outcome
post-marketing surveillance (all case surveillance) on treatment with alhemo® in patients with haemophilia a or haemophilia b with inhibitors

Conditions: Haemophilia A; Haemophilia B

Summary: the purpose of the study is to investigate the safety and effectiveness of alhemo® in all participants under real-world clinical practice in japan. participants will get alhemo® as prescribed by the study doctor. the study will last for about 2 years.


Eligibility criteria:
inclusion criteria: * signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) * the decision to initiate treatment with commercially available alhemo® has been made by the patient/lar and the treating physician before and independently from the decision to include the patient in this study * male or female patients, regardless of age * diagnosis with hawi/hbwi exclusion criteria: - previous participation in this study. participation is defined as having given informed consent in this study